Literature DB >> 16302817

Small molecule inhibitors of dynamin I GTPase activity: development of dimeric tyrphostins.

Timothy Hill1, Luke R Odell, Jennifer K Edwards, Mark E Graham, Andrew B McGeachie, Jenny Rusak, Annie Quan, Ruben Abagyan, Janet L Scott, Phillip J Robinson, Adam McCluskey.   

Abstract

Dynamin I is a GTPase enzyme required for endocytosis and is an excellent target for the design of potential endocytosis inhibitors. Screening of a library of tyrphostins, in our laboratory, against the GTPase activity of dynamin I gave rise to a microM potent lead, 2-cyano-3-(3,4-dihydroxyphenyl)thioacrylamide (1, IC50 70 microM). Our initial investigations suggested that only the dimeric form of 1 displayed dynamin I GTPase inhibitory activity. Subsequent synthetic iterations were based on dimeric analogues and afforded a number of small molecules, low microM potent, inhibitors of dynamin I GTPase, in particular, symmetrical analogues with a minimum of two free phenolic -OHs: catechol-acrylamide (9) (IC50= 5.1 +/- 0.6 microM), its 3,4,5-trihydroxy congener (10) (IC50= 1.7 +/- 0.2 microM), and the corresponding 3-methyl ether (11) (IC50= 9 +/- 3 microM). Increasing the length of the central alkyl spacer from ethyl to propyl (22-24) afforded essentially identical activity with IC50's of 1.7 +/- 0.2, 1.7 +/- 0.2, and 5 +/- 1 microM, respectively. No decrease in activity was noted until the introduction of a hexyl spacer. Our studies highlight the requirement for two free amido NHs with neither the mono-N-methyl (86) nor the bis-N-methyl (87) analogues inhibiting dynamin I GTPase. A similar effect was noted for the removal of the nitrile moieties. However, modest potency was observed with the corresponding ester analogues of 9-11: ethyl ester (90), propyl ester (91), and butyl ester (92), with IC50's of 42 +/- 3, 38 +/- 2, and 61 +/- 2 microM, respectively. Our studies reveal the most potent and promising dynamin I GTPase inhibitor in this series as (22), which is also known as BisT.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16302817     DOI: 10.1021/jm040208l

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  16 in total

1.  Dynamin inhibition blocks botulinum neurotoxin type A endocytosis in neurons and delays botulism.

Authors:  Callista B Harper; Sally Martin; Tam H Nguyen; Shari J Daniels; Nickolas A Lavidis; Michel R Popoff; Gordana Hadzic; Anna Mariana; Ngoc Chau; Adam McCluskey; Phillip J Robinson; Frederic A Meunier
Journal:  J Biol Chem       Date:  2011-08-05       Impact factor: 5.157

2.  Synthesis of Dynole 34-2, Dynole 2-24 and Dyngo 4a for investigating dynamin GTPase.

Authors:  Mark J Robertson; Fiona M Deane; Phillip J Robinson; Adam McCluskey
Journal:  Nat Protoc       Date:  2014-03-20       Impact factor: 13.491

3.  Use of dynasore, the small molecule inhibitor of dynamin, in the regulation of endocytosis.

Authors:  Tom Kirchhausen; Eric Macia; Henry E Pelish
Journal:  Methods Enzymol       Date:  2008       Impact factor: 1.600

4.  The Rhodadyns, a New Class of Small Molecule Inhibitors of Dynamin GTPase Activity.

Authors:  Mark J Robertson; Gordana Hadzic; Joseph Ambrus; D Yuri Pomè; Emily Hyde; Ainslie Whiting; Anna Mariana; Lisa von Kleist; Ngoc Chau; Volker Haucke; Phillip J Robinson; Adam McCluskey
Journal:  ACS Med Chem Lett       Date:  2012-03-26       Impact factor: 4.345

5.  Drugs targeting dynamin can restore cytoskeleton and focal contact alterations of urinary podocytes derived from patients with nephrotic syndrome.

Authors:  Janina Müller-Deile; Beina Teng; Heiko Schenk; Hermann Haller; Jochen Reiser; Sanja Sever; Mario Schiffer
Journal:  Ann Transl Med       Date:  2016-11

6.  Regulation of dynamin oligomerization in cells: the role of dynamin-actin interactions and its GTPase activity.

Authors:  Changkyu Gu; Joann Chang; Valentina A Shchedrina; Vincent A Pham; John H Hartwig; Worawit Suphamungmee; William Lehman; Bradley T Hyman; Brian J Bacskai; Sanja Sever
Journal:  Traffic       Date:  2014-06-24       Impact factor: 6.215

7.  Receptor-mediated endocytosis generates nanomechanical force reflective of ligand identity and cellular property.

Authors:  Xiao Zhang; Juan Ren; Jingren Wang; Shixie Li; Qingze Zou; Nan Gao
Journal:  J Cell Physiol       Date:  2018-02-27       Impact factor: 6.384

8.  Pharmacological targeting of actin-dependent dynamin oligomerization ameliorates chronic kidney disease in diverse animal models.

Authors:  Mario Schiffer; Beina Teng; Changkyu Gu; Valentina A Shchedrina; Marina Kasaikina; Vincent A Pham; Nils Hanke; Song Rong; Faikah Gueler; Patricia Schroder; Irini Tossidou; Joon-Keun Park; Lynne Staggs; Hermann Haller; Sergej Erschow; Denise Hilfiker-Kleiner; Changli Wei; Chuang Chen; Nicholas Tardi; Samy Hakroush; Martin K Selig; Aleksandr Vasilyev; Sandra Merscher; Jochen Reiser; Sanja Sever
Journal:  Nat Med       Date:  2015-05-11       Impact factor: 53.440

9.  Building a better dynasore: the dyngo compounds potently inhibit dynamin and endocytosis.

Authors:  Adam McCluskey; James A Daniel; Gordana Hadzic; Ngoc Chau; Emma L Clayton; Anna Mariana; Ainslie Whiting; Nick N Gorgani; Jonathan Lloyd; Annie Quan; Lia Moshkanbaryans; Sai Krishnan; Swetha Perera; Megan Chircop; Lisa von Kleist; Andrew B McGeachie; Mark T Howes; Robert G Parton; Michael Campbell; Jennette A Sakoff; Xuefeng Wang; Jian-Yuan Sun; Mark J Robertson; Fiona M Deane; Tam H Nguyen; Frederic A Meunier; Michael A Cousin; Phillip J Robinson
Journal:  Traffic       Date:  2013-10-09       Impact factor: 6.215

Review 10.  The glomerular filtration barrier: a structural target for novel kidney therapies.

Authors:  Ilse S Daehn; Jeremy S Duffield
Journal:  Nat Rev Drug Discov       Date:  2021-07-14       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.